CLEA Japan, Inc.

Nippon Crea is a main supplier of laboratory animals, as well as a non-clinical CRO. Various disease models are available.

The company has established an integrated in-house platform for animal quality control and testing. They have a wide range of client bases for research in immunology and metabolic related diseases.

Features of CLEA Japan, Inc.’s Non-Clinical Study Services

Comprehensive testing Platform based on laboratory animals

Nippon Crea can provide a comprehensive end-to-end support for non-clinical studies as a long-standing lab animals/ lab material supplier and also can perform in vivo studies and report preparation.

The company has a platform that allows clients to involve from the early stage study designing, such as test item planning, animal preparation, feed adjustment, and cage setup.

Nippon Crea ensures the quality and reliability of its contract studies as they have their own lab facility for in-house testing.

With a proven track record in area of regenerative medicine, the company is widely recognized as a reliable partner in advanced research.

Flexible support for both pharmacology and pharmacokinetics

Nippon Crea supports both pharmacodynamic and pharmacokinetic studies, offering comprehensive assistance from the research stage to practical applications.

In addition to efficacy evaluation in animal models, they provide a full range of ADME assessments— absorption, distribution, metabolism, and excretion.

By handling every step from experimental design to data analysis and GLP-compliant reporting, Nippon Crea provides precise and goal-oriented support that is tailored to each stage of the drug discovery process.

Animal welfare and quality management by international standards

Fully accredited by AAALAC International, Nippon Crea is compliant with global standards for animal welfare and research ethics.

Consistent quality control and traceability throughout breeding and reproduction processes ensure high reproducibility in their non-clinical studies.

They can also provide reliable testing platform with GLP standard for studies for pharmaceuticals and regenerative medicine, which has strict regulatory environment.

Example of a Disease Model Available at CLEA Japan, Inc.

Parkinson’s Disease Model Using 6-OHDA

For Parkinson’s disease—a representative neurodegenerative disorder—Nippon Crea offers a model using 6-hydroxydopamine (6-OHDA).

This model selectively damages dopaminergic neurons in the midbrain, reproducing symptoms such as tremors and motor dysfunctions.

It is applicable to preclinical studies aimed for investigating disease pathology and exploring novel therapeutic approaches, and is also available as a part of the company’s non-clinical contract study services.

Reference: https://www.clea-japan.com/promotion/previous_service/parkinson

Non-Clinical Case Study byCLEA Japan, Inc.

Microbiome Study Support Utilizing Gut Microbiota

Nippon Crea also provides microbiome studies focusing on the correlation between gut microbiota, immune function, and many other symptoms of the disease.

They can support the discovery of disease biomarkers, pharmaceuticals and functional foods.

Nippon Crea offers flexible study designs tailored to specific research needs. Clients can expect thorough protocol consultation, study execution and timely reporting. This can also be utilized at the initial screening stage as a non-GLP study.

Reference: https://www.clea-japan.com/products/service/item_c0050

Corporate Information